| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We have demonstrated that neuroblastoma (NB) subcutaneously implanted in immuno-competent mice is eliminated by intratumoral administration of poliovirus (PV). Our results also suggested that the in vivo destruction of NB cells by virotherapy lead to a robust antitumor immune response. Since we used CD155-transfected NB for experiments, CD155 might be a target for antitumor immune response. Although NB can grow in naive mice, no tumor growth was observed in mice cured of NB that were reinnoculated with NB cells. Splenocytes harvested from NB-bearing mice treated with PV exhibited higher lytic activity against NB cells than did those from splenocytes derived from naive mice. In vitro T-cell depletion experiments indicated that CD8+ T cells were essential for the cytotoxic antitumor activity of splenocytes.
|
